Update on raloxifene: Mechanism of action, clinical efficacy, adverse effects, and contraindications

Obstetrical and Gynecological Survey

Volumn 68, Issue 6, 2013, Pages 467-481

  Gizzo, Salvatore ^a   Saccardi, Carlo ^a   Patrelli, Tito Silvio ^b   Berretta, Roberto ^b   Capobianco, Giampiero ^c   Gangi, Stefania Di ^a   Vacilotto, Antonio ^a   Bertocco, Anna ^a   Noventa, Marco ^a   Ancona, Emanuele ^a   D'Antona, Donato ^a   Nardelli, Giovanni Battista ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; RALOXIFENE; TAMOXIFEN; TELOMERASE REVERSE TRANSCRIPTASE;

ADVERSE DRUG REACTION; ARTICLE; BLOOD CLOTTING; BONE DENSITY; BONE DEVELOPMENT; BONE METABOLISM; BONE TISSUE; BREAST; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; COLLAGEN SYNTHESIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOMETRIUM; ENDOMETRIUM CANCER; FRAGILITY FRACTURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LONG TERM CARE; MENOPAUSAL SYNDROME; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PROTEIN EXPRESSION; QUALITY OF LIFE; SYSTEMATIC REVIEW; TREATMENT DURATION; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM;

BLOOD COAGULATION; BONE AND BONES; BREAST; BREAST NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; OSTEOPOROSIS; RALOXIFENE; RECEPTORS, ESTROGEN; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THROMBOEMBOLISM;

EID: 84878539661     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e31828baef9     Document Type: Article

References (50)

1. Riggs BL, Hartmann LC. Selective estrogen-receptor modulatorsV mechanisms of action and application to clinical practice.NEngl J Med. 2003;348: 618-629.
2. FDA Approval for Raloxifene Hydrochloride. National Cancer Institute, September 2007. Available at: http://www.cancer.gov/cancertopics/druginfo/fda- raloxifene-hydrochloride. Accessed November 25, 2012.
3. Stefanick ML. Risk-benefit profiles of raloxifene for women. N Engl J Med. 2006;355: 190-192.
4. Rey JR, Cervino EV, Rentero ML, et al. Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice. Open Orthop J. 2009;3: 14-21.
5. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell. 2004;5: 207-213.
6. Messalli EM, Scaffa C. Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. Int J Womens Health. 2010;1: 11-20.
7. Taranta A, Brama M, Teti A, et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone. 2002;30: 368-376.
8. Gianni W, Ricci A, Gazzaniga P, et al. Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab. 2004;89: 6097-6099.
9. Compston JE. Sex steroids and bone. Physiol Rev. 2001;81: 419-447.
10. Viereck V, Gru? ndkerC, Blaschke S, et al. Raloxifene concurrently stimulates osteoprotegerin and inhibitsinterleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab. 2003;88: 4206-4213.
11. Messalli EM, Mainini G, Scaffa C, et al. Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas. 2007;56: 38-44.
12. Moen MD, Keating GM. Raloxifene: a review of its use in the prevention of invasive breast cancer. Drugs. 2008;68: 2059-2083.
13. Lopes-Costa PV, dos Santos AR, dos Santos LG, et al. Evaluation of Ki-67 and Bcl-2 antigen expression in breast carcinomas of women treated with raloxifene. Cell Prolif. 2010;43: 124-129.
14. dos Santos LG, da Silva BB. The effect of raloxifene on telomerase expression in breast carcinoma samples from postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 2011;159: 165-167.
15. da Silva BB, dos Santos AR, Pires CG, et al. Effect of raloxifene on vascular endothelial growth factor expression in breast carcinomas of postmenopausal women. Cell Prolif. 2009; 42: 506-510.
16. Todorova VK, Kaufmann Y, Luo S, et al. Tamoxifen and raloxifene suppress the proliferation of estrogen receptorYnegative cells through inhibition of glutamine uptake. Cancer Chemother Pharmacol. 2011;67: 285-291.
17. Bläuer M, Heinonen PK, Rovio P, et al. Effects of tamoxifen and raloxifene on normal human endometrial cells in an organotypic in vitro model. Eur J Pharmacol. 2008;592: 13-18.
18. Helvering LM, AdrianMD, Geiser AG, et al. Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in the rat uterus. Biol Reprod. 2005;72: 830-841.
19. Flamini MI, Sanchez AM, Goglia L, et al. Differential actions of estrogen and SERMs in regulation of the actin cytoskeleton of endometrial cells. Mol Hum Reprod. 2009;15: 675-685.
20. Morishima S, Shibata MA, Ohmichi M, et al. Raloxifene, a selective estrogen receptor modulator, induces mitochondriamediated apoptosis in human endometrial carcinoma cells. Med Mol Morphol. 2008;41: 132-138.
21. Azevedo GD, Franco RF, Baggio MS, et al. Procoagulant state after raloxifene therapy in postmenopausal women. Fertil Steril. 2005;84: 1680-1684.
22. Sgarabotto M, Baldini M, Dei Cas A, et al. Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study. Thromb Res. 2007;119: 85-91.
23. Surazynski A, Jarzabek K, Haczynski J, et al. Differential effects of estradiol and raloxifene on collagen biosynthesis in cultured human skin fibroblasts. Int J Mol Med. 2003;12: 803-809.
24. Nanetti L, Camilletti A, Francucci CM, et al. Role of raloxifene on platelet metabolism and plasma lipids. Eur J Clin Invest. 2008;38: 117-125.
25. Chen LY, Metha JL. Inhibitory effect of high-density lipoprotein on platelet function is mediated by an increase in nitric oxide synthase activity in platelets. Life Sci. 1994;55: 1815-1821.
26. Martino S, Cauley JA, Barrett-Connor E, et al. CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96: 1751-1761.
27. Johnston CC Jr, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebocontrolled trials. Arch Intern Med. 2000;160: 3444-3450.
28. Delmas PD, Ensrud KE, Adachi JD, et al. Multiple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87: 3609-3617.
29. Siris ES, Harris ST, Eastell R, et al. Continuing Outcomes Relevant to Evista (CORE) Investigators. Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res. 2005; 20: 1514-1524.
30. Jolly EE, Bjarnason NH, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause. 2003;10: 337-344.
31. Barrett-Connor E, Mosca L, Collins P, et al. Raloxifene Use for the Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355: 125-137.
32. Vogel VG, Costantino JP, Wickerham DL, et al. National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295: 2727-2741.
33. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 2001;65: 125-134.
34. Grady D, Cauley JA, Geiger MJ, et al. Raloxifene Use for The Heart Trial Investigators. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst. 2008;100: 854-861.
35. Visvanathan K, Lippman SM, Hurley P, et al. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Gynecol Oncol. 2009;115: 132-134.
36. Vogel VG, Costantino JP, Wickerham DL, et al. National Surgical Adjuvant Breast and Bowel Project. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila). 2010;3: 696-706.
37. Cohen FJ, Watts S, Shah A, et al. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol. 2000;95: 104-110.
38. Punyadeera C, Kamps R, Defrère S, et al. Effects of selective oestrogen receptor modulators on proliferation in tissue cultures of pre- and postmenopausal human endometrium. J Steroid Biochem Mol Biol. 2008;112: 102-109.
39. Goldstein SR, Scheele WH, Rajagopalan SK, et al. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol. 2000;95: 95-103.
40. de Azevedo GD, do Prado MF, Ferriani RA, et al. Raloxifene therapy does not affect uterine blood flow in postmenopausal women: a transvaginal Doppler study. Maturitas. 2004;47: 195-200.
41. Walsh BW, Kuller LH,Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279: 1445-1451.
42. de Leo V, laMarca A, Morgante G, et al.Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol. 2001;184: 350-353.
43. Piperi C, Zisaki K, Skenderi K, et al. Evidence of improved serum fatty acid profile of postmenopausal women receiving atorvastatin and raloxifene. J Obstet Gynaecol. 2005;25: 476-481.
44. Vogelvang TE, Mijatovic V, van der Mooren MJ, et al. Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women. Maturitas. 2005;50: 312-320.
45. Oztas E, Kurtay G. Randomized, controlled study of the effects of raloxifene on high sensitivity C-reactive protein and serum lipids. Arch Gynecol Obstet. 2011;283: 71-77.
46. Grady D, Ettinger B, Moscarelli E, et al. Multiple Outcomes of Raloxifene Evaluation Investigators. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol. 2004;104: 837-844.
47. Lippuner K, Buchard PA, De Geyter C, et al. Recommendations for raloxifene use in daily clinical practice in the Swiss setting. Eur Spine J. 2012;21: 2407-2417.
48. Cohen FJ, Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas. 2000; 34: 65-73.
49. Usall J, Huerta-Ramos E, Iniesta R, et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2011;72: 1552-1557.
50. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285: 785-795.